Helene Vanacker

Faculté De Médecine Lyon Est, 
Lyon, FR 
Faculté De Médecine Lyon Est, 
Lyon, FR 

Overview

Helene Vanacker practices practicing medicine in Lyon, France.

Her clinical expertise encompasses Adult Soft Tissue Sarcoma, Synovial Sarcoma, Ovarian Cancer, and Alveolar Soft Part Sarcoma.

She is actively involved in clinical research, co-authoring 43 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Faculté De Médecine Lyon Est, Lyon, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based Chemotherapy
Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based Chemotherapy
Enrollment Status: Completed
Publish Date: March 18, 2026
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
A Multicentre, Comparative, Placebo-controlled, Double-blinded, Phase II Study of the Efficacy of Lenvatinib in Patients With Locally Advanced or Metastatic GIST After Failure of Imatinib and Sunitinib
A Multicentre, Comparative, Placebo-controlled, Double-blinded, Phase II Study of the Efficacy of Lenvatinib in Patients With Locally Advanced or Metastatic GIST After Failure of Imatinib and Sunitinib
Enrollment Status: Completed
Publish Date: June 18, 2024
Intervention Type: Other, Drug
Study Drug: Lenvatinib
Study Phase: Phase 2
View 1 Less Clinical Trial

43 Total Publications

Mutation type, tyrosine kinase function in normal cell and tyrosine kinase inhibitor activity in cancers.
Mutation type, tyrosine kinase function in normal cell and tyrosine kinase inhibitor activity in cancers.
Journal: Scientific reports
Published: November 05, 2025

Frequently Asked Questions about Helene Vanacker

Is Helene Vanacker a top-rated expert for Adult Soft Tissue Sarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Helene Vanacker is classified as an Experienced expert for Adult Soft Tissue Sarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Helene Vanacker participate in research or clinical trials?

Yes. Helene Vanacker has published 43 articles and abstracts on conditions like Adult Soft Tissue Sarcoma. You can view a list of Helene Vanacker's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Vanacker's expertise for a condition
ConditionClose
        View All 10 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile